Rockeby Announces R&D Appointments

Rockeby Announces R&D Appointments

Australia, 10 March 2005 Rockeby biomed Limited (ASX:RBY) today announced the following appointments in the company's R&D department located in Perth.

Dr John Warmington, Director of Research & Development at Rockeby biomed (Australia) Pty Ltd will relinquish his position and assume a consultancy role as Chief Scientist with immediate effect. Dr Warmington will remain as Executive Director of Rockeby biomed (Australia) Pty Ltd and as Non-Executive Director of Rockeby biomed Limited, the ASX listed company of the Rockeby biomed Group of Companies.

Dr Warmington was instrumental in the Research & Developmental phases of Rockeby's two products namely SysCan3(r), a multi-well Elisa based hospital test kit and CanDia5(r), the world's first and only blood-based professional point of care diagnostic test kit. Dr Warmington will continue to play an important role as Chief Scientist as the company continues to commercialize new diagnostic products in the future pipeline.

Dr David Capes Ph.D, Head, Product Development, Diagnostics Division at Rockeby biomed (Australia) Pty Ltd will be promoted to Vice President - Research & Development with immediate effect. Dr Capes, was previously Director of R&D (Asia-Pacific) with Becton Dickinson where he oversaw a staff of 35 and a multi-million dollar budget. He has more than 20 years' pharmaceutical industry experience.

Dr Capes played an important role in the last year in Rockeby's US FDA 510(k) application, the ISO and Quality Management System, and CE Mark certification processes that has enabled Rockeby to achieve ISO certification and CE Mark approval ahead of schedule.

Dr Capes will continue to conduct research and development activities in line with corporate strategies and carry out product development of new diagnostic products.

Rockeby biomed is an ASX-listed (ASX: RBY) biotechnology company engaged primarily in the research, development and marketing of products for the diagnosis and treatment of fungal infections in humans. The company's main market is that of in-vitro diagnostic testing which covers serology tests in hospitals as well as point-of-care products for use by consumers or health professionals operating outside hospitals.

ENDS

© Scoop Media